PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer
Open Access
- 1 January 2017
- journal article
- research article
- Published by Taylor & Francis in Drug Delivery
- Vol. 24 (1) , 1818-1830
Abstract
Vascular-targeted photodynamic therapy (PDT) is an important strategy for cancer therapy. Conventional vascular-targeted PDT has been achieved by passive photosensitizer (PS) delivery, which involves a high risk of adverse effects. Active PS delivery is urgently required for vascular-targeted PDT. Although endothelial cells and pericytes are major cellular components of tumor blood vessels, little attention has been paid to pericyte-targeted PDT for cancer therapy. PDGFRβ is abundantly expressed in the pericytes of various tumors. In this experiment, a dimeric ZPDGFRβ affibody with a 0.9 nM affinity for PDGFRβ was produced. The ZPDGFRβ affibody showed PDGFRβ-dependent pericyte binding. Intravenously injected ZPDGFRβ affibody was predominantly distributed on pericytes and thus accumulated in LS174T tumor grafts. The conjugate of the ZPDGFRβ affibody and IR700 dye, i.e. ZIR700, bound to PDGFRβ+ pericytes but not to PDGFRβ− LS174T tumor cells. Accordingly, ZIR700-mediated PDT in vitro induced the death of pericytes but not of LS174T tumor cells. In mice bearing LS174T tumor grafts, ZIR700-mediated PDT damaged tumor blood vessels, thus inducing tumor destruction by intensifying tissue hypoxia. The average mass of tumor grafts administered with ZIR700-mediated PDT was approximately 20–30% of that of the control, indicating that pericyte-targeted PDT is efficient for cancer therapy. In addition, ZIR700-mediated PDT increased the tumor uptake of TNF-related apoptosis-inducing ligand (TRAIL) injected post-illumination. Consequently, combination therapy of ZIR700-mediated PDT and TRAIL showed greater tumor suppression than ZIR700-mediated PDT- or TRAIL-based monotherapy. These results demonstrated that active vascular-targeted PDT could be achieved by using ZPDGFRβ affibody-directed delivery of PS.Keywords
This publication has 35 references indexed in Scilit:
- Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full AntibodyPLOS ONE, 2013
- Heptameric Targeting Ligands against EGFR and HER2 with High Stability and AvidityPLOS ONE, 2012
- Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor BetaMolecular Imaging and Biology, 2012
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane moleculesNature Medicine, 2011
- Targeted photodynamic therapy — a promising strategy of tumor treatmentPhotochemical & Photobiological Sciences, 2011
- Conjugation of cRGD Peptide to Chlorophyll a Based Photosensitizer (HPPH) Alters Its Pharmacokinetics with Enhanced Tumor-Imaging and Photosensitizing (PDT) EfficacyMolecular Pharmaceutics, 2011
- Use of a HEHEHE Purification Tag Instead of a Hexahistidine Tag Improves Biodistribution of Affibody Molecules Site-Specifically Labeled with 99mTc, 111In, and 125IJournal of Medicinal Chemistry, 2011
- Engineered High-Affinity Affibody Molecules Targeting Platelet-Derived Growth Factor Receptor β In VivoJournal of Molecular Biology, 2011
- Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast CancerThe American Journal of Pathology, 2009
- Photodynamic therapy for cancerNature Reviews Cancer, 2003